Yousif Capital Management LLC Has $61.43 Million Position in Eli Lilly and Company $LLY

Yousif Capital Management LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 80,504 shares of the company’s stock after selling 687 shares during the quarter. Eli Lilly and Company comprises 0.7% of Yousif Capital Management LLC’s portfolio, making the stock its 14th largest holding. Yousif Capital Management LLC’s holdings in Eli Lilly and Company were worth $61,425,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth $27,000. Sumitomo Mitsui Financial Group Inc. acquired a new position in Eli Lilly and Company during the 2nd quarter worth $27,000. Evolution Wealth Management Inc. bought a new stake in Eli Lilly and Company during the second quarter valued at about $29,000. Steph & Co. boosted its holdings in Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after acquiring an additional 29 shares during the period. Finally, Financial Gravity Companies Inc. acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at about $31,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.5%

LLY opened at $1,077.06 on Thursday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The firm’s fifty day moving average price is $976.10 and its two-hundred day moving average price is $837.36. The company has a market capitalization of $1.02 trillion, a P/E ratio of 52.69, a P/E/G ratio of 1.08 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the prior year, the company posted $1.18 EPS. The business’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on LLY shares. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Morgan Stanley lifted their price target on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a research report on Monday, November 24th. Loop Capital set a $950.00 price objective on Eli Lilly and Company in a research report on Monday, November 10th. National Bankshares set a $1,286.00 price objective on shares of Eli Lilly and Company in a research note on Monday, December 1st. Finally, Wolfe Research upped their target price on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,155.36.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.